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BACKGROUND: Bringing new therapies to patients
with rare diseases depends in part on optimizing
clinical trial conduct through efficient study start-up
processes and rapid enrollment. Suboptimal execution
of clinical trials in academic medical centers not only
results in high cost to institutions and sponsors, but
also delays the availability of new therapies. Addressing
the factors that contribute to poor outcomes requires
novel, systematic approaches tailored to the institution
and disease under study.
OBJECTIVE: To use clinical trial performance metrics
data analysis to select high-performing cystic fibrosis
(CF) clinical research teams and then identify factors
contributing to their success.
DESIGN: Mixed-methods research, including semi-
structured qualitative interviews of high-performing
research teams.
PARTICIPANTS: CF research teams at nine clinical
centers from the CF Foundation Therapeutics Develop-
ment Network.
APPROACH: Survey of site characteristics, direct ob-
servation of team meetings and facilities, and semi-
structured interviews with clinical research team mem-
bers and institutional program managers and leaders in
clinical research.
KEY RESULTS: Critical success factors noted at all
nine high-performing centers were: 1) strong leader-
ship, 2) established and effective communication within
the research team and with the clinical care team, and
3) adequate staff. Other frequent characteristics includ-
ed a mature culture of research, customer service
orientation in interactions with study participants,
shared efficient processes, continuous process improve-
ment activities, and a businesslike approach to clinical
research.
CONCLUSIONS: Clinical research metrics allowed iden-
tification of high-performing clinical research teams.
Site visits identified several critical factors leading to
highly successful teams that may help other clinical
research teams improve clinical trial performance.
KEY WORDS: clinical trials; qualitative research; quality improvement;
clinical research metrics; benchmarking; process improvement; cystic
fibrosis.
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INTRODUCTION
The implementation of clinical trials is complex and
involves the interactions of multiple components, including
the center research team, the study sponsor, a contract
research organization, and institutional services such as the
institutional review board (IRB) and the contracts and
budgets office. Effective communication between the
clinical research team and clinical care team may also be
necessary to identify research participants. Sub-optimal
conduct of clinical trials in academic medical centers both
raises the costs to institutions and sponsors and delays the
availability of new therapies.1 The slow development of
protocols, redundant scientific and ethical reviews, and
protocol requirements that hinder enrollment contribute to
the inferior conduct of clinical trials in academic centers.2–4
In 2006, the Clinical and Translational Science Award
(CTSA) program of the National Institutes of Health (NIH)
was developed to support a national consortium of
biomedical research institutions to accelerate progress in
clinical research. The NIH subsequently requested pro-
posals for work that would improve processes related to the
development, approval, activation, enrollment, and comple-
tion of clinical trials.
The limited patient population available for clinical trials
in rare diseases makes optimization of clinical trial conduct
even more relevant to these affected patients. The Cystic
Fibrosis Foundation’s Therapeutics Development Network
(TDN), including 77 centers, was established in 1998 to
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accelerate the testing of new therapeutics, collect data on
the natural history of CF through observational studies, and
test the utility of new outcome measures for people with
cystic fibrosis.5 Because 31 of the 77 TDN centers were
also CTSA institutions that had collected clinical trial
metrics data, it was possible to identify high-performing
centers and evaluate their clinical research practices.
The aim of this project was a collaborative benchmarking
inquiry6,7 to identify the critical factors that enable high-
performing clinical research teams to excel at clinical trial
initiation and study execution. We aimed to use clinical trial
performance metrics data to identify centers with superior
performance, and then mixed methods, including semi-
structured qualitative interviews, to identify common
success factors.
METHODS
Selection of Centers to Benchmark
Clinical Study Metrics Data Collection and Analysis. All
CF TDN centers contribute study metrics quarterly into a
web-accessed database for each TDN study. Data collected
include the number of patients enrolled and the time from
regulatory packet receipt to: 1) Institutional Review Board
(IRB) approval, 2) contract execution, 3) approval to enroll
(site activation), and 4) first patient enrolled.
Analyzing study metrics for a network of research
centers, even within the same disease entity, is complicated
by variations in the study portfolio of each TDN center. No
studies include all 77 of the network centers; rather, each
sponsor selects participating centers based on requirements
of the protocol. Furthermore, because each study has its
own factors that influence study metrics, normalization of
the metrics data is required to compare centers within the
network and to identify centers with consistently superior
performance.
Normalization for Enrollment. We developed a scoring
algorithm to weight the enrollment data according to study
complexity and burden. The weighting score considers
observational vs. interventional study, duration, complexity
of procedures, visit intensity (many visits over a shorter
period of time), restrictiveness of inclusion/exclusion
criteria, and ease of working with the sponsor (e.g.,
responsiveness to inquiries, quality of materials provided,
and ease of budget and contract negotiation). The weighting
scores for each study were evaluated and approved by the
TDN Steering Committee, a group of 15 TDN principal
investigators and research coordinators from different
network centers. The weighting scores range from 0.1
(single-visit observational studies) to 3.0 (highly complex
long-duration interventional studies). Enrollment is
normalized by calculating a percent weighted enrollment
for each center:
Center X Weighted Enrollment
Total number of CF Patients ¼ 250
Enrollment in Study #1 : 8 subjects; Weighting Score ¼ 1:5;Weighted Enrollment ¼ 12
Enrollment in Study #2 : 10 subjects;Weighting Score ¼ 0:8; Weighted Enrollment ¼ 8
CenterX Percent Weighted Enrollment ¼ 12þ 8ð Þ=250 ¼ 8%
Normalization for Start-up Timing. Start-up timing metrics
are normalized for each study by performing quartile analyses
for each of the key start-up milestones. For example, on a 40-
center study, the first ten centers to achieve the milestone of
first patient enrolled would receive a quartile score of 4, the
next ten centers a quartile score of 3, and so on, with the
slowest ten centers receiving a quartile score of 1. For each
center, an average quartile score is calculated for each of the
start-up milestones by summing the quartile scores for that
milestone and then dividing by the number of studies with data
for that milestone.
During the time period assessed for this study, 67 multi-
center studies (with at least four participating centers)
provided data for analysis. To select highly successful
centers, the start-up milestone deemed most important was
the time to first patient enrolled, since it reflected the
efficiency of the entire study start-up process.
To select centers for benchmarking visits, we conducted a
composite analysis that plotted the average quartile score
for time to first patient enrolled against the percent
weighted enrollment for each center (Fig. 1). The latter
was considered more important.
The subset of data for the 31 CTSA centers was used to select
centers for benchmarking using data from two time periods (10/
1/06–9/30/08 and 10/1/08–3/31/10 [month/day/year]). Later in
the project, a small non-CTSA center (Center E) was added to
represent similar centers. We selected seven centers with
sustained high performance (generally within the upper right
quadrant of Fig. 1 for each of the two periods evaluated) and
two centers (Centers C and G) with the greatest improvement in
enrollment (at least twofold) between the first and second
evaluation periods. We also considered center size (small to
large) and CF translational focus (none to significant) in making
our selection. As a final step, we solicited informal feedback
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from study sponsors to confirm that the centers we had selected
were also perceived as delivering quality data (i.e., general
perceptions of responsiveness and acceptable rates for protocol
violations, subject completion, and queries). This feedback
resulted in the exclusion of several centers that might have been
selected on the basis of the metrics data analysis alone.
CONDUCTING THE BENCHMARKING ACTIVITIES
Realist Evaluation Framework. We applied the realist
evaluation framework to our benchmarking strategy and the
development of the semi-structured interview questions.8
Realist evaluation is a mixed-methods approach that begins
with a practical theory about what works under specific
circumstances and then refines and improves the theory based
on testing using qualitative and quantitative data collected
over time. The realist evaluation approach is based on a
formula: mechanism + context = outcomes. Mechanisms are
processes that trigger and produce reactions to generate
outcomes in specific contexts, while contexts are defined as
places or settings in which the mechanisms work and in which
the outcomes are produced. The “theory of the case” thus
specifies a prediction or explanation about what happens
(mechanisms) in specific research institutions (contexts) to
produce changes in performance (outcomes). Our team
developed a theory about the success characteristics of high-
performing centers (Fig. 2) that was evaluated and refined
based on data collected during the benchmarking research.
Investigational Team. The benchmarking protocol
development and site-visiting team included personnel
with significant experience in clinical research
management, CF investigators and research coordinators,
and CF clinical care and quality improvement scientists
from several universities (Seattle Children’s Hospital
Research Institute/University of Washington, University of
North Carolina at Chapel Hill, University of Pittsburgh and
Dartmouth) and the CF Foundation.
Data Collection and Analysis. All centers selected for
benchmarking were approached, agreed to the visit
requirements, and were visited between July and November
2010. The site visit included an initial meeting with the clinical
research team to present an overview of the program’s structure
and processes. Each team member was given a questionnaire
developed around the theory of the case and asked to select the
five factors from those listed that they believed were most
important to their team’s success (Online Appendix 1).
Notably, key team members were asked to complete the
questionnaires before our interviews and were given only the
brief description of each characteristic included in the
questionnaire when providing their rankings. The following
day, the site visitors observed a research team meeting, toured
the facilities, and conducted individual interviews (TDN
principal investigators and lead research coordinators/
managers) or group interviews (including other members of
the research team).When possible, institutional leadership such
as CTSA program directors or department chairs, IRB
managers, and contracts office managers were also
interviewed to assess institutional characteristics. Although
the interview questions were primarily designed to probe the
theory of the case, open-ended questions were also included to
allow center participants to describe factors and processes not
Figure 1. Composite analysis of start-up timing and enrollment success. Each dot represents a single center. The Y axis shows the average
quartile score for the metric of time from regulatory package receipt to first patient enrolled. A quartile score of 4 indicates that a center is
in the fastest 25 % for that particular metric. The X axis shows the percentage of a center’s total CF patient population (weighted for study
complexity) enrolled into studies during two consecutive evaluation periods, the first lasting 24 months and the second 18 months. Dotted
lines mark the medians for these metrics during the designated time period. Centers represented in the (shaded) upper right quadrant had
start times that were generally faster and enrolled a greater proportion of their patients in clinical studies compared to other centers. Letters
designate centers selected for benchmarking. These centers showed either sustained high performance or significant improvement between
the first and second evaluation periods.
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specifically addressed (Online Appendix 2). Our approach
during site visits and interviews was appreciative inquiry,
which acknowledges achievement and seeks to identify the
reasons for success.9
The research plan was approved by the Seattle Children’s
Institutional Review Board. All interviews were recorded and
transcribed, and the interview information was analyzed using
content analysis software (Atlas.ti., Berlin, Germany) to code
individual quotes into various themes. The results of the
interview content analysis were integrated with questionnaire
data and observer notes using an iterative process, and cross-
case methodology10 was applied. For each center, an individual
case study summary was written, then reviewed and edited by
the site visitors. Finally, each center reviewed its own case
summary to confirm that key concepts had not been missed.
RESULTS
Institutional Context and Outcomes. The centers ranged in
size from 101 to 454 patients, with five of nine centers visited
having adult CF populations that made up more than half of
the patient population served. (Table 1) All teams had weekly
research meetings. The ratio of research staff to patient
population spanned nearly a threefold range. Center staff and
investigators noted a variety of challenges: (1) working across
two institutions (Centers A and D), (2) significant travel time
between staff offices and research visit space (Centers F and I),
(3) low ratio of research staff to CF patient population (Centers
B, C, F and G), and (4) institutional barriers to timely start-up
[Center H (IRB) and Center I (contract)]. However, as
reflected in each center’s overall success, the clinical
research teams were able to compensate for these challenges.
Top-Ranked Success Factors for Benchmarked Centers.
For each center, the five factors that were mentioned most
frequently in the individual questionnaires are noted in Table 2.
Teams were unanimous regarding the importance of shared
leadership between the principal investigator and research
coordinator, as well as the importance of communication
between the clinical care and research teams and the value of a
customer-service orientation to interactions with study
participants. However, what was perceived as important varied
considerably for all of the other factors. For example, the centers
that identified the longevity of their research staff as being most
important did not see either structured training or regular
meetings as highly important, while those that did not identify
longevity did identify those two factors as important. This
suggests that teamswith newer staff dependedmore on structured
communication and training than more experienced staff did.
Key Success Characteristics Based on Interviews and
Observation. Table 3 presents the characteristics identified by
site visitors based on their observations and the interviews.
Leadership, effective communication, and adequate staff to
complete the work were identified at all centers.
Leadership. Leadership was highly ranked in the
questionnaire and in the interviews. The presence of at
least one highly engaged leader and a model of shared
leadership were universally valued. The shared leadership
Figure 2. A priori theory of the case. We established this list of likely mechanisms of success based on information gathered between 1998
(when the CF TDN was established) and 2010 through informal discussions, workshops, and training sessions with TDN centers. Our site
selection process allowed us to evaluate centers with different institutional contexts by including centers of varying size and translational
focus, centers located in densely populated urban areas as well as centers located in smaller cities, some centers with nearby competing
programs, and varying levels of institutional resources for all centers.
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might be between a pediatric and adult principal
investigator, or between the principal investigator and
research coordinator. The most valued qualities of
leadership included a visible commitment to TDN studies
and goals, availability to the team, the solicitation of team
opinions in decision-making, and in particular, attention to
team workload. The two centers selected for benchmarking
visits based on their observed improvement reported that
the primary reason for the change were new team leaders
who focused on improvement and used metrics data to
compare their study performance to peer institutions.
Effective Communication. The diverse components of the
clinical research process within an institution are linked
through effective communication. This was demonstrated
through regular research team meetings, close interaction
between clinical research and clinical care teams, and shared
expectations for responsiveness to calls and email
correspondence. Communication was also facilitated by
physically placing team members near one another and near
the clinical program, where conversation could replace email.
Staff Adequacy. This refers to a broad range of team qualities,
including having staff whose skills match the work, having a
sufficient number of coordinators and support staff, and ensuring
that the total number of studies managed by the team does not
exceed the staff’s capacity. In general, comments about what
attributes were sought when hiring came from centers that had
recently recruited new staff. Three of the four centers with a low
ratio of research support staff to patients (C, F, and G) were the
largest centers, suggesting that there may be some efficiencies of
scale. However, most of these centers had recently experienced
turnover and planned to hire additional staff.
One key characteristic we identified had not been included in
the theory of the case: the importance of a businesslike approach
to the financial sustainability of the program. This strategy
includes the development of adequate study budgets, enrolling
the number of subjects specified within the contract, financial
tracking to ensure that payments due have been received, and
examining final accounting to inform future budgeting.
We had anticipated that a culture of research would be a
key success factor, but did not expect that such a large
amount of time and effort would be necessary to develop
such a culture. For many centers, the effort had been an
essential part of the program for years. Clinical research
was woven into discussions in clinic visits from infancy
through adulthood, and reflected a longstanding general
focus on CF research in the program (basic, translational
and clinical). In other centers, having a culture of research
was only recently recognized as a success characteristic,
and intentional activity to develop such a culture had begun
only a few years before our benchmarking work.
DISCUSSION
Critical success factors noted at all nine high-performing
centers were strong leadership, established and effective
Table 1. Institutional Context and Outcomes for the Nine Benchmarked Centers
Center
A B C D E‡ F G H I


















Separate Adult and Pediatric Institutions Yes No No Yes No No No No No
Combined Adult/Pediatric Research Support
Staff
No* Yes Yes Yes Yes Yes Yes Yes Yes
CF Translational Research Focus|| ++ + +++ + - +++ ++ +++ ++
Staff Travel Time (Minutes) to Research Visit
Location
5 0 0 5 0 15 5 0 10
Estimated FTE for Research Support Staff† 4.6 1.5 3.8 5.0 1.6 3.5 4.0 5.0 5.0
Number of Research Staff per 100 Patients with
CF at Site
1.5 0.9 1.0 2.2 1.6 0.8 0.9 1.5 1.9
Average Quartile Time to IRB Approval§ 2.5 2.6 2.5 2.8 3.8 2.9 2.5 1.8 3.3
Average Quartile Time to Contract Execution§ 3.3 3.5 2.2 2.4 3.0 2.3 2.6 2.2 1.7
Average Quartile Time to Activation§ 2.7 3.3 2.3 2.8 3.2 3.0 2.4 1.8 2.4
Average Quartile Time to First Patient
Enrolled§
3.3 2.7 2.2 3.1 3.0 2.2 2.4 2.5 2.7
*The pediatric research team was the primary focus of the review because at the time of the benchmarking, adult subjects were recruited by the
pediatric research team and were seen at the pediatric center for research visits
†Research support staff included research managers, research coordinators (both nurse and non-nurse), laboratory staff, regulatory document
coordinators, budget and contract support. All teams had some dedicated CF clinical research staff, while some teams also had institutional support
for various functions (for which FTE was estimated). There was variation within each research team regarding the specific personnel and who
performed which function
‡Center E was not a CTSA Awardee
§ The average quartile time presented in this table comes from Period 2 (10/1/2008 – 3/31/2010). For comparison, the average quartile time for the
23 CTSA sites that were not benchmarked was 2.1 or 2.2 for all milestones
||Centers were categorized as having no (−), limited (+), moderate (++), or significant (+++) translational focus based on the amount of basic and
investigator-initiated CF research being conducted at the institution
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communication within the research team and with the
clinical care team, and adequate staff to complete the work.
Other frequent characteristics included a mature culture of
research, a customer service orientation in interactions with
study participants, shared efficient processes, continuous
process improvement activities, and a businesslike approach
to clinical research. We believe that collecting clinical trial
performance metrics is central to facilitating improvement
in clinical research, and have continued to monitor metrics
data for all centers in the network. Since 2009, TDN centers
have received annual metrics reports that compare their
performance with that of other centers in the network. This
allows them to identify potential areas for improvement and
to measure the impact of changes made over time.
Our theory of the case was largely confirmed and
reinforces the notion that the people comprising the team
are as important—if not more important—than specific
clinical research processes in achieving success. Some of
our findings were not predicted by our theory; specifically,
the attention paid to financial sustainability in some centers,
while others were less important than we expected (e.g., IT
systems to manage processes and a customer-service
orientation in interactions with sponsors). Overall, we
gained a rich understanding of how individual teams
leveraged different strengths to achieve similar goals.
Our initial assumptions regarding the importance of
multi-level shared leadership between the principal investi-
gator and the lead research coordinator were broadened to
reflect the variety of leadership structures observed at the
centers. We found that the strongest leadership could come
from the pediatric or adult program investigators, the lead
research coordinator, or the research manager. In some
cases, it was strong leadership from both adult and pediatric
investigators or an investigator and coordinator equally
sharing the role. Each of these models was effective and
depended on the people involved and the institutional
context. Not surprisingly, turnover of strong leadership
affects a team’s dynamics and performance. Such perturba-
tions force the team to adapt and provide another
opportunity to measure how some teams recover and
improve. Given the inevitability of staff turnover, those
who manage such disruptions well can share their strategies
for preserving team effectiveness or accelerating recovery.
We identified several apparent contradictions between the
forced rankings of success factors that each research team
member completed before their interview (Table 2) and the
actual observations and analysis of the interview content
(Table 3). For example, only one center ranked Process
Improvement as one of its top five factors, yet information
shared during the interview was coded to a category that
included process improvement, and it was deemed as a
significant contributor for six centers. We offer four factors to
explain these apparent discrepancies: 1) forcing team members
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Table 3. Specific Examples of the 12 Success Characteristics
Success Characteristic No. of
Centers*
Examples of How this Characteristic was Met Key Demonstrative Quotes
Leadership with Clinical
Research as a Priority
9 • Single highly motivated, engaged PI (either adult
or pediatric)
• Shared leadership between multiple engaged PIs
(both adult and pediatric)
• Shared leadership between the PI(s) and the
research coordinator or manager
“The heart of our program is the very strong
leadership of the Pediatric PI and the Adult PI.
Really, without them we would have maintained the
status quo.”
“If I had to say who has the greatest influence on
our team, I would have to say both the Pediatric PI
and the Research Manager.”
“He (PI) is very hands-on. He’ll sit down with us
rather than working us to death and say, ‘Let’s re-
evaluate, what can we do to get through this, how
can I help you?’ He really makes this a great job.”
Adequate Staff 9 • Recruit good staff looking for team player,
problem-solving skills, attention to detail, self-
motivation, and good fit with the rest of the team
• Enough staff for the work: monitor workload and
hire or improve processes (i.e., create efficiencies)
such that the existing staff can perform the work
• Focus on retention by providing opportunities for
growth
“I think you can have the best job descriptions and
all the funding you need, but if you don’t get good
people it’s a non-starter. And it’s a certain type of
person…the people that work in our program are all
self-starters who you don’t need to tell what to do.”
“When I interviewed her…her energy and how
quickly she learns things were so apparent to me,
and it didn’t take long for her to make key
contributions to our group.”
“You can’t be like the kid in the candy shop and
just keep going….you have to know when the staff
is at their limit.”
Effective Communication 9 • Regular research team meetings (adult and
pediatric staff)
• Research staff attend clinical care meetings
• Research staff share office space with clinical
colleagues
• Adult and pediatric research teams share office
space
• Responsiveness and clear communication of
expectations
“There is just great communication. Beyond the
communication about who is coming in and might
be eligible for a study, the research team does an
outstanding job of communication with us if there
is a clinical issue that they notice during a research
visit. We will often hear about changes in labs or
lung function. There is just a great interchange of
information.”
“The more you communicate with the sponsors and
the quicker you get things back to them, the quicker
they’re going to get things back to you. The only
way that I can do submissions so quickly is because
I call them and say, ‘I am willing to give you my
full attention for the next day and get this done for
you, but here is what I need from you.”
Customer Service 8 • Study visits scheduled at odd times of the day
and on weekends
• Attention paid to the comfort and convenience of
the study subjects
“The coordinators just have that attitude…’oh we
will make it work—we will find you a place to stay
when you’re in town, we will get you a gas card if
that’s a problem.’ The subject feels valued and that
they are important.”
“We really coddle our subjects. The coordinators
are just so flexible with them…. We’ll come in at
night, we’ll do stuff on the weekends, just do the
best we can to accommodate their schedules.”
“We really make an effort to see these people when
they are not participating in studies, which I think
they really appreciate because we see them as
people, not just research participants.”
Culture of Research 8 • Considered a shared responsibility for clinical
care and research teams
• Observational studies offered to subjects when
young
• Research team members attend all CF clinics to
meet patients, talk about research in general or
about specific studies
“Historically, no one was really approaching the
families…it just wasn’t part of the fabric of the center. I
give credit to the Pediatric and Adult PIs, because that
has visibly changed here. Families now know and
understand that we do research here.”
“Even before we had the Port CF registry, we had a
consent form for an in-house CF database. That
consent form gives permission to put their data in the
database, but also gets permission to have their data
reviewed for potential eligibility for studies. So it is
right up front that research is part of the culture here.”
(continued on next page)
S720 Retsch-Bogart et al.: Characteristics of Effective Clinical Research Teams JGIM
Table 3. (continued)
Success Characteristic No. of
Centers*
Examples of How this Characteristic was Met Key Demonstrative Quotes
Continuous Process
Improvement Driven by the
CF Research Team
6 • CF team approached institutional offices to work
on reducing time for key milestones (IRB or
contract approval)
• Fixing problems as soon as they arise
• Regularly polling staff about what is working,
what isn’t, and what they need
“We did a QI project last year when we got our
metrics and we did not like our number of days
from regulatory packet to final contract.”
“It’s the denial part….you’ve got this whole list of
excuses, but then you realize that other centers face
similar challenges but are doing better. It was a
great motivator for us to see how underperforming
our center was compared to others. So we presented
it (our metrics report) to the group and started
talking about ideas to help improve recruitment.”
“About three times a year, I ask them individually a
list of questions: What’s working? What’s not
working?” Is there someone I should recognize who
has really made your job or life better? Do you
have the tools you need to do your job?”
Great Team Dynamics 6 • Shared vision about the value of the work being
done
• Getting to know each other outside of work
• Research teams work together to raise money for
CF research
“There is a program-wide sense of commitment and
camaraderie. We all not only work together here,
but we all turn out for Great Strides [fund-raising
event]. There is this whole sense of community that
this is something that really matters.”
Shared, Efficient Processes 5 • Longevity of staff resulted in shared processes
that were not always written down
• Written processes, checklists, white boards
• Shared calendars
• Mock or practice study visit prior to study
initiation
“There is an order in which we do things, these are
the things we do simultaneously, this our time
frame. There is a lot of meticulous cross checking
and people keep things up to date and filed so that
you can go back and find things.”
“I am just constantly in awe of how well it’s run
and how organized everyone is, from all these
boards telling me what trials are coming up and
when all of the subject visits are.”
“We prep well in advance anything that we could
possibly need at a subject visit, it’s all right there.
“You are never running around saying, ‘oh, I need
this or I need that’…It’s already put together and
ready.”
Business-like Approach 5 • Develop adequate study budgets that cover all
costs, and team understands the risk of financial
loss if enroll fewer than planned number of
subjects
• Institution allows IRB, budget, and contract
activities to run simultaneously (not consecutively)
to improve speed of start-up
“…sponsors and customers see us as an anomaly in
the academic world because we’ve made purposeful
decisions to be nimble, to be business-like, to be
aware of the world outside of here and to be
flexible if needed.”
“When we produce value, people will come back to
us for value and they will keep coming back to us
for value.”
IT Systems 3 • Databases used to identify potential subjects
• Electronic tracking systems used to facilitate and
monitor processes, financial accountability, and
metrics
“We involve our data management group…and I
think that this has been instrumental in
transforming both clinical care and research. We
can send them inclusion/exclusion criteria, and
within 24 hours we have the exact number of
subjects who potentially meet eligibility”
Balance of CF Programs 2 • Adult and pediatric research teams equally
invested in research
• Clinical care and research are equally valued
• Basic research also valued
“As the clinical director, it is really important for us
to empower the research people, to let them know
that we want them involved…not that it is just OK
if you come by to talk to this patient about a study,
but that we WANT you to come and talk to this
patient about that study.”
Institutional Support of
Clinical Research
2 • Institution supports research activities (budget
development, contract negotiation, regulatory
document preparation, pool of research
coordinators)
• Institution provides adequate, well-located space
for research visits and research staff office space
“It really helped when we moved. We didn’t use to
have office space together, but now we are on the
same floor, we see each other every day….we just
talk more.”
*Number of visited centers where this characteristic was identified as a key contributor of success.
CF = cystic fibrosis, IT = information technology, PI = principal investigator, QI = quality improvement
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other important factors ; 2) team members completed the
questionnaires and performed forced rankings before the
interviews, relying on the brief description in the questionnaire;
3) the coding process used for the interview content and site
visitor observations changed over time to group commonly
cited, related themes together into a specific coded category; and
4) the interview questions themselves may have solicited more
comments about some themes than others.
Our study has several limitations. Our selection of centers was
not entirely driven by data, but was modified by additional
factors, such as observations by others regarding study quality
and our decision to pick a broad range of centers by size and
research environment. Although we used a consensus approach
to develop the benchmarking protocol, bias is inevitable when
creating a theory of the case, which then guides the content of the
questionnaires and interview guides. The technique of apprecia-
tive inquiry focuses primarily on what is going well rather than
what is not going well, and therefore may introduce positive
biases. We studied only centers that were highly successful,
which prevented us from formally comparing characteristics of
centers with average or below-average performance; to see if
these differed substantially in centers that were less successful.
The content analysis approach relies on grouping data into
themes by the same investigators who developed the study,
which also introduces bias. We observed only a small number of
centers and made our observations during a single time period
rather than in multiple visits over an extended period; thus, we
could not prospectively assess how teams cope with new
challenges. Our analysis of the institutional context was limited
to a few factors. We did not pursue an in-depth examination of
factors that could affect success in recruitment, such as
demography, socioeconomic profile, population density of
patients served in the region where the center is located,
presence of competing clinical research centers in large
metropolitan areas, and distance patients traveled to the center.
During the interview process, we were able to determine the CF
research team’s perceptions of institutional research support (and
were able to observe the physical facilities available to the
research teams); however, we did not systematically evaluate the
institutional review boards, contracts and grants offices, or other
institutional clinical research offices.
Through this work, we identified a number of modifiable
factors common to high-performing centers. If these factors
are unique or if particular combinations of them are
associated with high performance, they may be character-
istics that set these teams apart. However, because we were
not able to use quantitative methods, we cannot offer
evidence to support a causal association between the factors
at high-performing centers compared to those with average
or below-average performance. We were able to assess the
context or institutional setting in only a limited way, so it is
possible the factors we identified at high-performing centers
may be more dependent on the institution than we
appreciated, making them less transferable to other teams.
Modifiable factors include those that may be adapted by any
study team regardless of institutional context, such as regular
team meetings, use of white boards to share key information,
use of checklists to ensure consistent and efficient processes,
sharing space to facilitate communication, and providing
flexible hours in the evening and weekend for study visits.
Establishing strong connections and a presence in the clinical-
care setting facilitates informing the clinical team about research
studies, and is a venue for explaining clinical research to
patients outside of recruitment to specific studies.
For clinical research teams who wish to improve their
performance, familiarity with the basic principles and standard
methods of quality improvement is a first step. This includes an
understanding of change models, the importance of systems-
based approaches, an appreciation of group dynamics, and
quantitative assessment of the impact of changes made.
Collecting and tracking the team’s study metrics (start-up and
enrollment) represent such measures, which can be extended
more broadly to the institutional or research network level.
Our benchmarking work identified several key factors
and practices associated with clinical research success that
can be modified by study teams. Clinical research teams
may find these observations useful as they undertake their
own quality improvement work through assessing their
clinical research performance, identifying suitable targets
for improvement, and considering strategies or practices to
adopt. We would anticipate that such changes would
enhance the experience of clinical research for study
participants and teams alike, as well as improve the conduct
and completion of clinical trials.
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